HR+/HER2- breast cancer is among the most common breast cancer subtypes, affecting a large patient population globally. As oncology research advances, innovative drug candidates are emerging, poised to revolutionize HR+/HER2- breast cancer treatment. These breakthroughs promise enhanced efficacy, better patient outcomes, and a shift in market dyna